Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37040070.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0422 and PMC identifier 10261915.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors of a recent study identified noncanonical peptides (NCP) presented by cancer cells' HLA and observed lack of reactivity to these antigens by endogenous tumor-reactive T cells. In vitro sensitization generated NCP-reactive T cells that recognized epitopes shared by a majority of cancers tested, providing opportunities for novel therapies to shared antigens. See related article by Lozano-Rabella et al., p. 2250.
Medical subject headings
- Melanoma
- Proteogenomics